Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLYC SEC filings page on Stock Titan offers access to regulatory documents associated with GlycoMimetics, Inc. before and through its business combination with Crescent Biopharma, Inc. GlycoMimetics described itself as a late clinical-stage biotechnology company focused on glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and inflammatory diseases. Its filings provide formal detail on this research focus, its investigational candidates, and the corporate transactions that culminated in the transition to Crescent Biopharma, Inc.
Key filings include current reports on Form 8-K that describe material events. For example, a June 18, 2025 Form 8-K explains that on June 13, 2025, GlycoMimetics consummated a business combination with Crescent Biopharma, Inc., and that after the merger the company changed its name to Crescent Biopharma, Inc. and its ordinary shares trade on The Nasdaq Capital Market under the symbol CBIO. This filing also outlines how GlycoMimetics and Crescent securities were converted in the merger and summarizes ownership percentages of the post-merger company.
Another Form 8-K dated July 31, 2025, filed under the Crescent Biopharma, Inc. name, describes the adoption of an executive severance plan for employees at the vice president level and above. Such filings provide insight into governance, compensation arrangements, and the structure of executive protections in connection with corporate change-of-control events.
On Stock Titan, users can review these and other GLYC-related filings with the support of AI-powered summaries that highlight key terms, transaction structures, and governance provisions. Real-time updates from EDGAR ensure that newly filed 8-Ks and other forms associated with the historical GLYC registration are captured. For investors and researchers examining the legacy GlycoMimetics entity and its merger into Crescent Biopharma, this page serves as a focused entry point into the company’s regulatory history and the documentation of its transition to trading under CBIO.
Form 3 highlights for GlycoMimetics Inc. (now Crescent Biopharma, Inc.)
On 06/23/2025 Fairmount Funds Management LLC and its affiliated investment vehicle Fairmount Healthcare Fund II L.P. filed an Initial Statement of Beneficial Ownership (Form 3) following the closing of a complex restructuring that included (i) a two-step merger between GlycoMimetics, Inc. and privately held Crescent Biopharma, Inc. completed on 06/13/2025 and (ii) a redomicile from Delaware to the Cayman Islands effective 06/16/2025.
Equity position disclosed
- Ordinary shares: 1,387,866 shares held indirectly by Fairmount Healthcare Fund II L.P.
- Series A Non-Voting Convertible Preferred Shares: 2,890 shares, convertible into 2,890,000 ordinary shares; no expiration date and subject to a beneficial-ownership cap.
- Pre-funded warrants: 1,636,706 warrants exercisable at $0.001 per share; no expiration date but capped at 9.99% ownership upon exercise.
Aggregating the ordinary shares, the preferred share conversion amount, and underlying warrant shares, Fairmount controls or can acquire up to approximately 5.9 million ordinary shares. This exceeds the 10 % ownership threshold, and the filing confirms the filer’s dual status as both a director by deputization (through Peter Harwin) and a 10 % beneficial owner.
Key structural details
- Each Crescent common share exchanged for 0.1445 ordinary shares of the issuer.
- Each share of Crescent Seed Preferred exchanged for 0.0001445 Series A Preferred Shares.
- All Crescent pre-funded warrants exchanged 1:1 (0.1445 ratio applied) into issuer pre-funded warrants.
No cash consideration, valuation data, or earnings metrics are provided in the Form 3. The filing mainly establishes the post-merger and post-redomicile capital structure and confirms Fairmount’s governance role and sizable equity stake.
Form 3 Overview: David Charles Lubner filed an initial statement of beneficial ownership following the closing of GlycoMimetics Inc.’s reverse-merger with Crescent Biopharma on 13 June 2025 and the company’s subsequent redomiciliation to the Cayman Islands on 16 June 2025. At the effective time, GlycoMimetics adopted the new corporate name “Crescent Biopharma, Inc.”.
Reporting person & role: Lubner is disclosed as a director; no other insider roles were indicated.
Securities reported:
- 20,164 stock options to purchase ordinary shares at an exercise price of $9.56 per share.
- 1,120 options already vested; the remaining 19,044 vest monthly through 14 April 2028, contingent on continued service.
Corporate actions referenced:
- Two-step merger whereby Crescent became a wholly owned subsidiary and GlycoMimetics simultaneously renamed itself Crescent Biopharma, Inc.
- Conversion of the Delaware corporation into a Cayman Islands exempted company; all existing options automatically converted into equivalent Cayman ordinary-share options.
This filing is administrative in nature, providing baseline ownership for a newly appointed director after the merger and redomiciliation. No open-market purchases, sales, or new compensatory grants were disclosed beyond the option rollover.
Form 3 overview: Director Susan Moran filed an initial beneficial ownership report following GlycoMimetics, Inc.’s transformative merger with Crescent Biopharma and immediate re-branding to Crescent Biopharma, Inc. ("Issuer"). The filing date of record is 13 Jun 2025.
Equity position disclosed: Moran holds a single derivative security—an option to purchase 20,164 ordinary shares at an exercise price of $6.16, expiring 11 Dec 2034. Of these, 3,360 options are fully vested; the remaining 16,804 vest in equal monthly tranches through 11 Dec 2027, contingent on continued board service.
Corporate actions driving the filing:
- Two-step merger (First Merger & Second Merger) completed 13 Jun 2025: GlycoMimetics created and merged two wholly-owned subsidiaries with Crescent Biopharma, leaving Crescent as a wholly-owned operating subsidiary.
- Post-merger, GlycoMimetics adopted the Crescent Biopharma name.
- Re-domicile: On 16 Jun 2025 the Issuer converted from a Delaware corporation to a Cayman Islands exempted company. All outstanding U.S. equity awards were automatically converted into rights over Cayman ordinary shares on identical terms.
Implications for investors: The Form 3 itself does not alter outstanding share count or economics, but it formalises insider ownership under the new capital structure, confirms option continuity across the merger and re-domicile, and signals that governance reporting has transitioned to the Cayman entity.
Schedule 13D/A Amendment No. 1 filed on 20 June 2025 discloses that Adage Capital Management, L.P., its co-founders Robert Atchinson and Phillip Gross (together, the “Reporting Persons”) now beneficially own 50,912 ordinary shares of Crescent Biopharma, Inc. (formerly GlycoMimetics, Inc.) after the issuer’s 1-for-100 reverse stock split and completion of a merger/redomestication on 13-16 June 2025.
The stake represents 0.37 % of the 13,892,562 shares outstanding, pushing the Reporting Persons below the 5 % threshold that triggers Schedule 13D reporting. No share transactions occurred in the past 60 days; the percentage change is entirely attributable to the share-count increase that accompanied the merger. As a result, this filing is designated the final amendment; Adage and its principals are voluntarily exiting the beneficial-ownership reporting system for the issuer.
Voting and dispositive power remain shared among the Reporting Persons, with no sole power disclosed. Adage Capital Partners retains rights to dividends and sale proceeds. The amendment contains no indication of future investment intentions or disposition plans.